Cargando…

Association between drug intake and incidence of malignancies in patients with Juvenile Idiopathic Arthritis: a nested case–control study

BACKGROUND: Several medications for treatment of Juvenile Idiopathic Arthritis (JIA) are considered to be carcinogenic. Therefore, the aim was to assess whether there is an association between therapeutic interventions and malignancies in JIA patients. FINDINGS: A nested case–control study was carri...

Descripción completa

Detalles Bibliográficos
Autores principales: Barth, Swaantje, Schlichtiger, Jenny, Bisdorff, Betty, Hügle, Boris, Michels, Hartmut, Radon, Katja, Haas, Johannes-Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4739096/
https://www.ncbi.nlm.nih.gov/pubmed/26842529
http://dx.doi.org/10.1186/s12969-016-0066-8
Descripción
Sumario:BACKGROUND: Several medications for treatment of Juvenile Idiopathic Arthritis (JIA) are considered to be carcinogenic. Therefore, the aim was to assess whether there is an association between therapeutic interventions and malignancies in JIA patients. FINDINGS: A nested case–control study was carried out within a retrospective cohort study of 3698 JIA patients diagnosed between 1952 and 2010. All 48 JIA patients with a diagnosis of a malignant tumour and up to four matched controls for each received a questionnaire about their use of medication. Subsequently treatment was compared between cases and controls and analyses performed for 37 cases and 125 controls (response 88.5 %). Treatment with DMARD (84 %) was most frequently used, followed by glucocorticoids (66 %) and immunosuppressives (65 %). Twenty percent reported to have ever been taking biologics. Medication use did not differ significantly between cases and controls. CONCLUSIONS: Our results did not show an association between medications used and malignancies in JIA patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12969-016-0066-8) contains supplementary material, which is available to authorized users.